Showing results (11-20 of 122) with videos related to
Sort By:
Pageof 13
The Lancet. Oncology|November 29, 2008
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findingsEnrique M Ocio, María-Victoria Mateos, Patricia Maiso, et al.Cells|November 27, 2019
Biological Background of Resistance to Current Standards of Care in Multiple MyelomaPedro Mogollón, Andrea Díaz-Tejedor, Esperanza M Algarín, et al.Clinical Lymphoma, Myeloma & Leukemia|February 19, 2026
FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML PatientsMercedes Colorado, Mª Aranzazu Bermúdez, Carmen Montes, et al.Expert Review of Clinical Pharmacology|June 20, 2022
Melflufen for the treatment of multiple myelomaEnrique M Ocio, Omar Nadeem, Fredrik Schjesvold, et al.American Journal of Hematology|March 30, 2005
Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomenaEnrique M Ocio, Fermin M Sanchez-Guijo, Maria Diez-Campelo, et al.Cancer Research|June 3, 2006
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistancePatricia Maiso, Xonia Carvajal-Vergara, Enrique M Ocio, et al.Clinical Lymphoma|March 30, 2005
Cell cycle analysis of Waldenstrom's macroglobulinemiaEnrique M Ocio, Gema Mateo, Belen Vidriales, et al.Journal of Clinical Medicine|September 30, 2020
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple MyelomaMaría-Victoria Mateos, Joan Bladé, Sara Bringhen, et al.British Journal of Haematology|March 18, 2008
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cellsPatricia Maiso, Enrique M Ocio, Mercedes Garayoa, et al.Molecular Cancer Therapeutics|January 17, 2014
Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategyXi Chen, Elena Díaz-Rodríguez, Enrique M Ocio, et al.Pageof 13